India’s Section 3(d): The Definitive IP Strategy Guide for Pharmaceutical and Biotech Companies
A technical deep dive for pharma IP teams, R&D leads, and institutional investors on the world’s most consequential pharmaceutical patent […]
U.S. vs. China Pharmaceutical Patent Strategy: The Definitive Analyst’s Guide to IP Valuation, Enforcement, and Competitive Positioning
A comparative deep dive for pharma and biotech IP teams, R&D leads, and institutional investors navigating the two most consequential
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The Economic Imperative of Time In the pharmaceutical sector, time is a tangible asset with a valuation that often exceeds
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook
1. The Pricing Crisis in Numbers The United States spends more per capita on prescription drugs than any other OECD
Precision Medicine Drug Pricing: The Complete IP, Patent, and Market Access Playbook Read Post »
What Happens When a Drug Patent Expires? Understanding Drug Patent Life
A strategic guide to patent expiry, lifecycle defense, and the economics of generic competition — for executives, investors, and analysts
What Happens When a Drug Patent Expires? Understanding Drug Patent Life Read Post »
FDA Tentative Approval: The Generic Drug Strategist’s Complete Playbook
1. What a Tentative Approval Actually Means (and What It Doesn’t) A Tentative Approval (TA) letter from the FDA means
FDA Tentative Approval: The Generic Drug Strategist’s Complete Playbook Read Post »
Pharmacists, PBMs, and Drug Price Wars: The Complete Analyst’s Guide to a Broken Distribution System
The three largest pharmacy benefit managers, CVS Caremark, Express Scripts (now Evernorth, the health services subsidiary of Cigna), and OptumRx
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook
Every year, dozens of brand-name drugs approach the end of their patent life with billions in annual revenue at stake.
Tentative Drug Approvals: The Definitive Generic Entry Forecasting Playbook Read Post »
Drug Patents vs. Prize Models: The Complete IP Strategy Guide for Pharma Innovation
How the incentive architecture behind pharmaceutical R&D shapes pipeline decisions, drug pricing, access policy, and $2 trillion in annual investment,
Drug Patents vs. Prize Models: The Complete IP Strategy Guide for Pharma Innovation Read Post »
